Related by context. All words. (Click for frequent words.) 69 Bezielle 69 CoFactor 69 HGS ETR1 69 OncoVEX GM CSF 68 PRTX 68 JAK inhibitor 68 Phase Ib study 67 HuMax CD4 67 TELCYTA 67 PXD# 67 oral prodrug 67 TELINTRA 67 PEG PAL 67 Azedra 67 PRT# 67 INCB# [001] 67 elotuzumab 67 PS# [001] 67 IRX 2 67 celgosivir 67 Amigal 67 valopicitabine 67 ALN TTR# 67 Altastaph 67 LEP ETU 66 talactoferrin 66 R#/MEM # 66 tanespimycin 66 DAVANAT 66 Traficet EN 66 MAXY G# 66 Proxinium TM 66 Phase 2a trial 66 Azixa 66 phase IIb clinical 66 IMA# 66 GRN#L 65 Phase 2b study 65 forodesine 65 picoplatin 65 MGCD# [001] 65 CRx 65 JAK1 65 Factor VIIa 65 preclinical studies 65 TREANDA 65 dacetuzumab 65 PEG SN# 65 Phase Ib clinical 65 XL# [003] 65 Marqibo 65 cannabinor 65 SparVax TM 65 chemotherapy induced neutropenia 65 Viramidine 65 Allovectin 7 R 65 AzaSite Plus 65 Triolex 65 blinatumomab 65 belinostat 65 Poly ICR 65 RDEA# 65 Dacogen injection 65 BAY #-# 65 phase IIa clinical 65 custirsen 65 pralatrexate 65 LymphoStat B 64 Topical Interferon Alpha 2b 64 Cethromycin 64 HQK 64 AP# [003] 64 ganetespib 64 Insegia 64 Phase Ib 64 elagolix 64 Bicifadine 64 GALNS 64 Phase 2b trial 64 velafermin 64 ApoB SNALP 64 BCX# 64 ONTAK 64 EndoTAG TM -1 64 bevirimat 64 Protexia R 64 rNAPc2 64 subcutaneous formulation 64 Panzem R 64 AEG# 64 Perifosine 64 TKM ApoB 64 otelixizumab 64 Apoptone 64 Phenoptin 64 vidofludimus 64 Sym# 64 DOS# 64 MOZOBIL 64 eniluracil 64 Panzem R NCD 64 enzastaurin 64 CCX# 64 mertansine 64 CORT # 64 personalized immunotherapy 64 ENMD # 64 rindopepimut 64 Fodosine 64 pomalidomide 64 Chemophase 64 Androxal TM 64 CD# CEA 64 TYZEKA 64 dose cohort 64 ALN PCS 64 OvaRex R 64 NEUMUNE 64 XmAb# 64 MEK inhibitor 64 Archexin 64 Zerenex 64 TRIOLEX 64 preclinical 63 L BLP# 63 Alocrest 63 bafetinib 63 KNS # 63 Fibrillex TM 63 Targretin 63 OncoVEX 63 eltrombopag 63 histone deacetylase HDAC inhibitor 63 rFIXFc 63 NP2 Enkephalin 63 pan HDAC inhibitor 63 GLP toxicology studies 63 Personalized Immunotherapy 63 IMGN# 63 Phase IIb trials 63 HGS ETR2 63 Bortezomib 63 RhuDex ® 63 Symadex 63 OHR/AVR# 63 CTAP# Capsules 63 HuMax EGFr 63 investigational monoclonal antibody 63 alvespimycin 63 ELACYT 63 lesinurad 63 Multimeric 63 AQ4N 63 GRNVAC1 63 orally bioavailable 63 PLK1 SNALP 63 MBP# [001] 63 Nventa 63 YONDELIS 63 TACI Ig 63 Aurexis 63 CEQ# 63 dirucotide 63 thymalfasin 63 highly immunogenic 63 VQD 63 Chrysalin 63 Phase 1b trial 63 AEGR 63 FavId 63 volociximab 63 targeted radiotherapeutic 63 favorable pharmacokinetic profile 63 PDX pralatrexate 63 MyVax R 63 CUDC 63 ALN TTR 63 Phase 2b clinical 63 huC# DM4 63 biodefense countermeasure 63 Troxatyl 63 obatoclax 63 OXi# 63 CA4P 63 Octreotide 63 lomitapide 63 Phase IIa trial 63 NGX# 63 Factor IX 63 Phase 1b 63 Azedra TM 63 CR# vcMMAE 63 Glufosfamide 63 ruxolitinib 63 XL# XL# 63 SCH # 63 PNP inhibitor 63 MAGE A3 ASCI 63 histone deacetylase inhibitor 63 Phase Ib clinical trials 63 HuMax CD# 63 registrational 63 glufosfamide 63 APOPTONE 63 DPX Survivac 63 Allovectin 7 63 investigational humanized monoclonal antibody 63 nitazoxanide 63 TOCOSOL Paclitaxel 62 MDV# 62 Synavive 62 teduglutide 62 LE SN# 62 tiapamil 62 G#DT 62 C1 INH 62 CYT# 62 Plicera 62 telaprevir VX 62 PANVAC VF 62 registrational trial 62 Phase IIa clinical 62 Panzem 62 ISTODAX 62 cilengitide 62 INT# [002] 62 Vilazodone 62 NeuroVax TM 62 Neuradiab 62 Virulizin R 62 Poly ICLC 62 reslizumab 62 Debio 62 rhThrombin 62 BrachySil 62 Valortim R 62 RGB # 62 urocortin 2 62 budesonide foam 62 PSN# [002] 62 Civacir 62 bicifadine 62 refractory gout 62 HCD# [002] 62 hematological cancers 62 PSMA ADC 62 octreotide 62 CTCE 62 NEBIDO 62 eculizumab 62 AVN# [001] 62 ORENCIA ® 62 AZD# 62 RiVax TM 62 IND submission 62 BioVant 62 vosaroxin 62 Phase IIa trials 62 pradefovir 62 oral ridaforolimus 62 CXA 62 PDE4 inhibitor 62 TLK# 62 ALN VSP 62 huN# DM1 62 Cloretazine R VNP#M 62 RiVax ™ 62 TBC# 62 CINTREDEKIN BESUDOTOX 62 Stimuvax R 62 GFT# 62 perifosine 62 Phase 1a clinical 62 MEK inhibitors 62 Xcytrin R 62 Phase 2a 62 orally administered inhibitor 62 AeroLEF TM 62 Virulizin ® 62 Amplimexon 62 Homspera 62 nonclinical studies 62 Phase #b/#a clinical 62 ponatinib 62 Omacetaxine 62 MyVax ® 62 Phase IIb 62 eprotirome 62 pertuzumab 62 Tavocept 62 NU# [001] 62 KRN# 62 interferon gamma 1b 62 Xanafide 62 GED aPC 62 Phase 2a clinical trials 62 dose cohorts 62 RSD# 62 atacicept 62 Asentar 62 Phase IIb clinical trials 62 IoGen 62 ADVEXIN 62 SinuNase TM 62 HCV protease inhibitor 62 PEGPH# 62 PREOS 62 oritavancin 62 Tarvacin TM 62 #D#C# 62 micafungin 62 TKB# 62 FluCide 62 decitabine 61 MGd 61 tivozanib 61 Nuvion 61 MGCD# [002] 61 cancer immunotherapies 61 tesmilifene 61 SinuNase 61 rFVIIIFc 61 confirmatory Phase III 61 Phase Ia 61 OMAPRO 61 faropenem 61 Dalbavancin 61 Exelixis compounds 61 Valortim 61 Exelixis XL# 61 EFAPROXYN 61 successfully commercialize Iluvien 61 Aerosurf 61 Ramoplanin 61 iSONEP 61 INCB# [002] 61 preclinically 61 proteasome inhibitor 61 pivotal Phase III 61 amrubicin 61 Onalta 61 ROTARIX 61 lucinactant 61 IAP inhibitors 61 Zenvia ™ 61 Stimuvax 61 AZX# 61 mipomersen 61 Ophena 61 FASLODEX 61 EOquin TM 61 ISIS # 61 ZFP Therapeutic 61 MAb 61 Elotuzumab 61 liposomal formulation 61 LEVADEX 61 MAXY alpha 61 metaglidasen 61 FOLOTYN ® 61 Solazed TM 61 Onalta ™ 61 PEP# [003] 61 Azedra ™ 61 menadione 61 vilazodone 61 ularitide 61 APTIVUS 61 ALN RSV# 61 elacytarabine 61 pharmacodynamic 61 CD# antibody [001] 61 ASONEP 61 pegfilgrastim 61 Acute Radiation Syndrome ARS 61 trastuzumab DM1 T DM1 61 HuLuc# 61 LE DT 61 fidaxomicin 61 #ME# 61 Anturol 61 JAK2 inhibitors 61 incyclinide 61 docetaxel Taxotere R 61 pharmacokinetic PK study 61 Excellagen 61 castrate resistant prostate cancer 61 MVA BN R 61 BiTE antibody 61 Pimavanserin 61 tolevamer 61 solithromycin 61 Annamycin 61 Capesaris 61 romidepsin 61 DDP# 61 nucleotide analog 61 Phase #/#a trial 61 prokinetic agent 61 CD# monoclonal antibody 61 IDX# 61 TYGACIL 61 Generx TM 61 epothilone 61 Phenserine 61 virus HCV protease inhibitor 61 Phase Ib II 61 non nucleoside HCV 61 Lovaxin C 61 humanized monoclonal antibody 61 Locteron 61 Veronate 61 Fx #A 61 preclinical toxicology 61 tezampanel 61 Shigamabs ® 61 novel VDA molecule 61 Omigard 61 PROCHYMAL 61 JVRS 61 Imprime PGG 61 Myocet 61 PREOS R 61 myelofibrosis 61 dextromethorphan quinidine 61 orally dosed 61 torezolid phosphate 61 JAK inhibitors 61 CERVARIX 61 Alzhemed TM 61 CIMZIA TM 61 Antigenics QS 61 RSD# oral 61 palifosfamide 61 NEUVENGE 61 TNFerade 61 Bendavia 61 GSK # 61 inhibitor RG# 61 tezampanel NGX# 61 tamibarotene 61 MAP# 61 trivalent influenza vaccine 61 cobiprostone 61 depsipeptide 61 Onconase 61 RLY# 61 Phase IIIb clinical 61 UPLYSO 61 ATL# [001] 61 axitinib 60 QLT# 60 Xyfid TM 60 Vicinium TM 60 initiate Phase 1b 60 ELND# 60 maximally tolerated dose 60 Phase IIb trial 60 Excellarate 60 PROMACTA 60 mRCC 60 Carfilzomib 60 ZADAXIN ® 60 CYT# potent vascular disrupting 60 Allovectin 7 r 60 EOquin 60 THR beta agonist 60 posaconazole 60 voreloxin 60 ALTU 60 SEPET TM 60 Copegus ribavirin 60 PEG interferon 60 Rebif ® 60 Tyrima 60 HGS# 60 Guanilib 60 Cleviprex TM clevidipine 60 teriflunomide 60 ridaforolimus 60 investigational immunotherapy 60 RIGScan CR 60 iCo 60 lintuzumab 60 Actilon 60 IMC #B 60 Ozarelix 60 mapatumumab 60 IND enabling 60 EVIZON 60 Valortim ® 60 Corlux 60 bendamustine 60 Irinotecan 60 viral kinetics 60 SILENOR TM 60 INGN 60 Elagolix 60 LEUKINE 60 Preclinical studies suggest 60 Theratope 60 LY# [003] 60 velafermin belinostat 60 therapeutic antibody 60 Dasatinib 60 Aganocide 60 Phase IIa clinical trials 60 albinterferon alfa 2b 60 PS# DARA 60 HCV protease 60 Pemetrexed 60 synthetic retinoid 60 DXL# 60 leukemia AML 60 PCK# 60 TORISEL 60 Atiprimod 60 Radezolid 60 CBLC# 60 somatostatin analogue 60 octreotide acetate 60 Leukine ® 60 Tovaxin 60 PEG Interferon lambda 60 HGS ETR1 mapatumumab 60 XL# anticancer compounds 60 HDAC Inhibitor 60 ozarelix 60 Amrubicin 60 Anturol ® 60 Cethrin 60 StaphVAX 60 ATL# [002] 60 CD3 monoclonal antibody 60 Onco TCS 60 Interferon alpha 60 L DOS# 60 BrachySil TM 60 Telintra 60 CAMPATH 60 TYKERB 60 non nucleoside inhibitor 60 Aflibercept 60 Ophena TM 60 H#N# VLP vaccine 60 ISENTRESS 60 tesetaxel 60 Phase #/#a 60 HCV polymerase 60 DermaVir Patch 60 Phase 2a clinical 60 Icatibant 60 RiVax 60 Varespladib 60 GVAX ® 60 BiovaxID 60 BRIM2 60 Aptivus ® 60 S1P antibody 60 DB# [003] 60 Daclizumab 60 Interferon alfa 60 deforolimus 60 FACTIVE tablets 60 Universal Flu Vaccine 60 Surfaxin LS 60 SARMs 60 samalizumab 60 MGN# 60 generation antisense 60 sapacitabine 60 preclinical efficacy 60 targeting CD# 60 phase 2a 60 PRX# 60 neratinib 60 iclaprim 60 phase IIb 60 CBLB# 60 REOLYSIN ® 60 AzaSite TM 60 hepatitis C HCV 60 Relivar 60 ocrelizumab 60 APD# 60 VIR# 60 ZYBRESTAT 60 CCR9 antagonist 60 TG# [001] 60 DAVANAT R 60 immunomodulator 60 Genasense ® oblimersen 60 polymerase inhibitor 60 CB2 selective receptor agonist 60 Inhalation Solution 60 StaphVAX R 60 Alinia 60 riociguat 60 trastuzumab Herceptin 60 HEPLISAV TM 60 OvaRex ® MAb 60 TRC# 60 maturation inhibitor 60 TroVax ® 60 ARIKACE ™ 60 TRISENOX ® 60 Polymer Microspheres 60 Vitaxin 60 TG# [003] 60 immunogenicity 60 elvucitabine 60 XL# XL# XL# XL# 60 Nasulin 60 sipuleucel T 60 bavituximab 60 PROVENGE sipuleucel T 60 FOLOTYN 60 delta isoform 60 liprotamase 60 AAG geldanamycin analog 60 Neo Kidney Augment 60 VitiGam 60 recombinant polyclonal antibody 60 PD LID 60 Pradefovir 60 omega interferon 60 HCV polymerase inhibitor 60 sodium thiosulfate STS 60 diabetic neuropathic pain 60 ocular formulation 60 masitinib 60 castration resistant prostate cancer 60 rPA anthrax vaccine 60 sodium Injection 60 Phase IIB 60 Thiovir 59 lumiliximab 59 humanized anti 59 Phase 1b clinical 59 zanolimumab 59 INC# 59 JNJ Q2 59 Hsp# inhibitor 59 RAV# 59 Cellegesic 59 Hsp# Inhibitor 59 MT# MEDI 59 Dyloject TM 59 Solazed ™ 59 lintuzumab SGN 59 Tezampanel 59 Phase III Pivotal 59 BAL# [002] 59 IAP inhibitor 59 Zemiva TM 59 Menerba 59 nucleoside 59 Shigamabs R 59 TMC# [002] 59 radezolid 59 Cinryze ™ 59 Xcellerated T Cells 59 delafloxacin 59 Pivotal Phase III 59 T Pred 59 BZL# 59 Phase IIb clinical 59 Hepatitis C virus HCV 59 Pruvel 59 bardoxolone 59 Phase #b/#a trial 59 Allovectin 7 ® 59 darapladib 59 maribavir 59 DermaVir 59 tgAAC# 59 Phase 2b 59 ORENCIA R 59 CCR5 antagonist 59 mycophenolate mofetil 59 adecatumumab 59 pitavastatin 59 LB# [003] 59 ganaxolone 59 Belinostat 59 alvimopan 59 CORLUX 59 ketolide antibiotic 59 2 methoxyestradiol 59 SERMs 59 Zalbin 59 SNALP technology 59 Lixivaptan 59 #I TM# 59 systemic RNAi therapeutic 59 omacetaxine mepesuccinate 59 oral deforolimus 59 investigational hepatitis B 59 AzaSite Xtra 59 NVA# 59 systemic immunosuppressive drugs 59 Trastuzumab 59 ONCONASE 59 catheter occlusion 59 luliconazole 59 mitomycin 59 Huntexil 59 Q#IR 59 UVIDEM 59 CIMZIA ™ 59 Fc fusion protein 59 SAR# [004] 59 Golimumab 59 refractory CLL 59 antiviral efficacy 59 Trizytek 59 GAP #B# 59 Lenocta 59 ALISTA 59 Dextofisopam 59 cintredekin besudotox 59 Alpharadin 59 INVANZ 59 carfilzomib 59 BiovaxID TM 59 BIM #A# 59 APF# 59 phase IIa 59 Nanobody 59 satraplatin 59 immunostimulatory 59 Romidepsin 59 Lenocta TM 59 Zoraxel 59 dasatinib Sprycel ® 59 Ceflatonin 59 ecallantide 59 Neulasta ® 59 Telbivudine 59 sJIA 59 ProLindac 59 Clavis Pharma 59 oral treprostinil 59 pharmacokinetic PK 59 acyclovir Lauriad R 59 bremelanotide 59 TH# [003] 59 Tesetaxel 59 Liprostin 59 hematological malignancies 59 Besivance 59 Phase 2b clinical trials 59 Numax 59 NXL# 59 rhMBL 59 ataluren 59 ZFP Therapeutic TM 59 Elocalcitol 59 MYDICAR 59 FLT3 59 forodesine hydrochloride 59 Phase #b/#a 59 GAMMAGARD 59 Virulizin 59 IL# PE#QQR 59 NEUGENE 59 acetonide FA 59 stated Michelle Berrey 59 Ketotransdel 59 Tamibarotene 59 antibody MAb 59 somatostatin analogues 59 oral picoplatin 59 selective androgen receptor modulator 59 Immunotherapeutic 59 AMD# [003] 59 Sudhir Agrawal D.Phil 59 HSP# inhibitor 59 Anavex #-# 59 humanized antibody 59 danoprevir 59 relapsed refractory multiple myeloma 59 nalbuphine ER 59 Restanza 59 OMP #M# 59 ofatumumab 59 PEGylated interferon beta 1a 59 CRMD# 59 Thrombin 59 Trofex 59 Intravenous CP 59 Ceflatonin R 59 prucalopride 59 injectable formulation 59 VAPRISOL 59 tafamidis 59 imetelstat 59 rALLy 59 R#/MEM 59 Vascular Wrap 59 recurrent glioma 59 non metastatic osteosarcoma 59 EGFR HER2 59 Phase 1a 59 refractory multiple myeloma 59 balsalazide tablet 59 SinuNase ™ 59 raxibacumab 59 anticancer therapies 59 PLX cells 59 anti CD# antibodies 59 REG2 59 Genitope Corporation 59 GSK# [001] 59 Aryplase 59 Zemiva ™ 59 ImmunoVEX HSV2 59 MNTX 59 ISF# 59 SPRYCEL ® 59 relapsed multiple myeloma 59 Serdaxin 59 MYDICAR ® 59 Liposomal 59 drug ISA# 59 Velcade bortezomib 59 confirmatory Phase 3 59 docetaxel Taxotere ® 59 clinical trials 59 Æterna Zentaris 59 darinaparsin ZIO 59 pharmacodynamic PD 59 mifamurtide 59 pegylated liposomal doxorubicin 59 methylnaltrexone 59 myeloproliferative disorders 59 assessing T DM1 59 Dapagliflozin 59 refractory chronic lymphocytic 59 Mipomersen 59 BENLYSTA ® 59 Cerashield 59 indibulin 59 LibiGel ® 59 rALLy clinical trial 59 ceftazidime 59 NUVIGIL 59 anti CD3 monoclonal 59 Kuvan 59 RITUXAN 59 HepaGam B 59 samarium Sm 59 ara C 59 cethromycin 59 EVIZON TM squalamine lactate 59 ribavirin RBV 59 ostarine 59 YERVOY 59 Genz # 59 Luteinizing Hormone Releasing Hormone 59 orBec 59 forodesine HCl 59 PMX # 59 VA# [002] 59 CCR2 59 Spiegelmer ® 59 entinostat 59 anticancer compound 59 HERmark 59 RNAi therapeutic 59 sorafenib Nexavar 58 SUCCEED trial 58 omecamtiv mecarbil 58 Tarceva TM 58 ongoing Phase 1b 58 phase IIb trial 58 KSP inhibitor 58 HIV integrase inhibitor 58 JAK2 inhibitor 58 Stedivaze 58 Phase IIb Trial 58 Antiviral Activity 58 NB S# 58 Shigamabs 58 durable remissions 58 brostallicin 58 AVP #D# 58 TPI ASM8 58 TRANSDUR Sufentanil 58 XL# SAR# 58 Staphylococcus aureus Polysaccharide Conjugate 58 IV Busulfex 58 myeloproliferative diseases 58 nanoviricides 58 MEK inhibitor RDEA# 58 erlotinib Tarceva ® 58 AVONEX ® 58 Phase III clinical 58 Aurora kinase 58 OMNARIS Nasal Spray 58 pharmacokinetic studies 58 ZOSTAVAX 58 cangrelor 58 Aurora kinase inhibitor 58 visilizumab 58 VEGF Trap 58 Advexin 58 pharmacokinetic PK profile 58 Cetrorelix 58 Metastatic Melanoma 58 superficial bladder cancer 58 tolerability 58 Cloretazine ® 58 pediatric acute lymphoblastic 58 Aganocide ® 58 Oracea TM 58 Bavituximab 58 Pafuramidine 58 rHuPH# 58 Hybridon 58 ZK EPO 58 TKM Ebola 58 AEZS 58 Vivecon 58 ARIKACE 58 ZEVALIN ® 58 Alferon N 58 antitumor activity 58 polyclonal antibody 58 initiated Phase 1b 58 Reolysin 58 selective modulator 58 isoform selective 58 vascular disrupting agents 58 dasatinib 58 IMP# 58 immunomodulatory 58 CANCIDAS 58 veltuzumab 58 CCR5 mAb 58 Pralatrexate 58 Radilex 58 BEMA TM Fentanyl 58 alefacept 58 Degarelix 58 immunomodulatory therapy 58 octreotide implant 58 CYC# 58 Preclinical studies 58 plasma kallikrein inhibitor 58 pexiganan 58 tigecycline 58 metastatic CRC 58 Evoltra ® 58 anti EGFR antibody 58 evaluating tivozanib 58 Quinamed 58 ILUVIEN ® 58 GW# [003] 58 CRLX# 58 ATryn R 58 doripenem 58 PKC# 58 Genasense ® 58 PROVENGE 58 FOLPI 58 DOXIL 58 pharmacological chaperone 58 HEPLISAV 58 nanoviricide drug 58 ICA # 58 novel peptide 58 immunotherapeutic agent 58 Elvitegravir 58 FluBlok 58 TroVax 58 PrevOnco 58 thiazolides 58 CTA# Injection 58 punctal plug 58 Neo Urinary Conduit 58 Dacogen decitabine 58 edifoligide E2F Decoy 58 ELADUR 58 BeneFIX 58 multicenter Phase II 58 Treanda 58 standard chemotherapy regimen 58 Fludara ® 58 Gleevec resistant 58 daclizumab 58 naronapride 58 Oritavancin 58 sargramostim 58 PEGylated 58 midstage trials 58 Vandetanib 58 baminercept 58 PRECISE trial